Table 2.
Literature review of the risk of secondary malignancy or malignant transformation following stereotactic radiosurgery.
| Reference | Histology | n | Median Follow-up (years) | Crude Rate of Secondary Malignancy and Malignant Transformation | Latency (years) |
| Pollock et al., 2017 [23] | Variousa | 1142 | 9.0 | 0.7% (8 cases) | 2.8-13.8 |
| Wolf et al., 2019 [26] | Variousb | 4905 | 8.1 | 0.06% (3 cases) | 8.7-12.8 |
| Hasegawa et al., 2013 [43] | VS | 440 | 12.5 | 0.3% (1 case) | 5.5 |
| Rowe et al., 2007 [30] | Variousc | 4877 | 5.2 | 0.02% (1 case) | 8.0 |
| Frischer et al., 2018 [44] | VS | 426 | 5.1 | 0.2% (1 case) | 8.6 |
| Birckhead et al., 2016 [45] | NF2-associated meningioma | 15 | 9.3 | 0% (0 cases) | NA |
| Gao et al., 2019 [46] | NF2-associated meningioma | 35 | 8.0 | 0% (0 cases) | NA |
| Starke et al., 2014 [25] | AVM | 1309 | 7.8 | 0.2% (3 cases) | 8-19 |
a
Arteriovenous malformation, meningioma, vestibular schwannoma, pituitary adenoma, glomus tumor
b
Vestibular schwannoma, meningioma, arteriovenous malformation, trigeminal neuralgia, pituitary adenoma, hemangioblastoma, other schwannoma
c
Arteriovenous malformation, meningioma, vestibular schwannoma, cerebral metastasis, other tumor, other pathology
Abbreviations: vestibular schwannoma (VS), neurofibromatosis type 2 (NF2), arteriovenous malformation (AVM), non applicable (NA)